Thursday, November 19, 2026

Thermo Fisher Scientific launched Gibco VaxEvo CD 293 Medium for Adenovirus Vaccines

Thermo Fisher Scientific announced Gibco VaxEvo CD 293 Medium, a chemically defined, animal origin-free cell culture medium for suspension human embryonic kidney 293 (HEK293) cell growth and adenovirus production. Available in liquid and Advanced Granulation Technology (AGT) formats, the medium supports vaccine developers from early process development through scale-up and manufacturing. Gibco VaxEvo CD 293 Medium is built for vaccine process development scientists and upstream manufacturing teams at human and animal health vaccine manufacturers using suspension HEK293 cells for adenoviral vectors, adenovirus vaccines, and oncolytic virus production.

Why Chemically Defined Media Matter in Adenovirus Production

According to a peer-reviewed study published in AMB Express (May 2022, indexed on the National Institutes of Health’s PubMed Central), adenovirus vector vaccines are studied for their induction of cellular and humoral immunity, though HEK293 cell-specific adenovirus productivity decreases as infected cell density rises, a limitation known as the cell density effect. The AMB Express study notes that traditional basal culture media supplemented with plasma or serum have unclear compositions that increase batch-to-batch variability and viral contamination risk, whereas serum-free and chemically defined media reduce raw-material variation and eliminate animal-derived microbial contamination sources.

In the PubMed Central study, researchers evaluating suspension HEK293S cells found that commercial serum-free media formulations vary in cell expansion and adenovirus productivity, with a 1:1 mixture of HEK293 and MCD293 media scaled to a 3-liter bioreactor yielding an adenovirus titer of 3.0 x 10^10 infectious units per milliliter (IFU/mL) and a cell-specific virus yield of 4,167 IFU/cell at two days post-infection. On Thermo Fisher Scientific’s Virus Production Media & Reagents page, Gibco virus media are formulated to control nutrients, pH, and osmolality throughout development and scale-up.

Adenovirus Type 5 Titers and No-Feed Benchmarking

Thermo Fisher Scientific states that in laboratory benchmarking studies using HEK293 cells, VaxEvo CD 293 Medium supported average adenovirus type 5 (Ad5) titers comparable to select supplier media, with results reaching up to 5.7-fold higher titers in some comparisons. On Thermo Fisher Scientific’s Virus Production Media & Reagents page, comparative studies using suspension Gibco 293F cells and human Ad5 reported up to 5.7-fold higher average Ad5 titers than other HEK media tested and up to 94% peak viable cell density (VCD).

Comparing Unfed Performance Against Fed Benchmark Media

In benchmarking studies, VaxEvo CD 293 Medium demonstrated comparable or higher adenovirus titers without a dedicated feed compared with select benchmark media used with their recommended feeds. According to Peptide and Protein News’s coverage of the launch, the press release states VaxEvo CD 293 Medium matched selected supplier media on average Ad5 titer and reached up to 5.7-fold higher in some comparisons, while neither the release nor the product page names the competing media tested.

Liquid and AGT Package Formats, SKUs, and Pricing

Thermo Fisher Scientific’s catalog lists five SKUs for VaxEvo CD 293 Medium: liquid A4001085401 at $142.00, 1 L AGT A4001085501 at $138.00, 10 L AGT A4001085502 at $750.00, 100 L AGT A4001085503 at $6,800.00, and 10 kg AGT A4001085504 at $26,195.00. “Manufacturing readiness begins well before a process reaches the plant. The choices vaccine developers make during process development can shape how they evaluate performance, complexity and the path to scale,” said Alex Cherkassky, Vice President and General Manager of Thermo Fisher Scientific’s cell culture business.

Regulatory Documentation and Lot-to-Lot Consistency

According to Thermo Fisher Scientific’s product FAQ, defined and chemically defined media have known component concentrations that reduce batch-to-batch variability and contamination risks associated with animal-derived serum or hydrolysates while simplifying process verification and regulatory documentation. The product page also notes that lot-to-lot control and documentation support material qualification and advancement of vaccine programs with few process changes.

How Vaccine Process Teams Use Gibco Virus Production Media

Thermo Fisher Scientific’s Virus Production Media & Reagents page lists viral production workflows across Vero, Madin-Darby Canine Kidney (MDCK), HEK293, Baby Hamster Kidney 21 (BHK-21), Madin-Darby Bovine Kidney (MDBK), and Spodoptera frugiperda (Sf9/12) cell lines from early development through current Good Manufacturing Practice (cGMP) production. Defined Gibco formulations are also used across viral platforms including adenovirus, adeno-associated virus (AAV), and lentivirus (LV) systems from cell expansion and virus expression through purification and scale-up.

Shake-Flask Evaluation for Suspension HEK293 Processes

Peptide and Protein News notes that VaxEvo CD 293 Medium was tested with suspension Gibco 293F cells and human Ad5, and process teams can evaluate the no-feed claim by running VaxEvo unfed alongside an existing basal medium and feed in a single shake-flask study. The Viral Vaccine Resource Hub on Thermo Fisher Scientific’s site provides application notes, case studies, webinars, and technical documents covering cell culture, virus expression, and downstream processing.

Also Read: Keysight 6G Sensing Emulation Launches with Cohere Zak-OTFS

Thermo Fisher Scientific Bioprocessing Brands and Scale

Headquartered in Waltham, Massachusetts, Thermo Fisher Scientific Inc. (NYSE: TMO) reports annual revenue of approximately $45,000,000,000 and employs 100,000 people under Chairman and CEO Marc N. Casper. Per Thermo Fisher Scientific’s launch announcement, the company delivers technologies and pharmaceutical services through brands including Thermo Scientific, Applied Biosystems, Invitrogen, Gibco, Fisher Scientific, Unity Lab Services, Patheon, and PPD.

Questions about Gibco VaxEvo CD 293 Medium

What are the intended use restrictions for Gibco VaxEvo CD 293 Medium?

Gibco VaxEvo CD 293 Medium is labeled for research use or further manufacturing, and not for diagnostic use or direct administration into humans or animals. Upstream vaccine teams use the formulation during cell growth and viral expression stages ahead of downstream purification.

What other Gibco virus production media are listed in the catalog?

Alongside VaxEvo CD 293 Medium, Thermo Fisher Scientific’s virus production catalog includes Gibco CD 293 AGT Medium (12529012, 10 L at $1,234.00), OptiPRO SFM (12309019, 1,000 mL at $151.00), VP-SFM (11681020 at $144.00), CD BHK-21 Production Medium (A1627703, 10 kg at $3,185.00), and Sf-900 III SFM (12658035, 10 L at $1,172.00). Both adherent and suspension media options are available across those catalog lines.

Which complementary reagents and custom media services support Gibco virus media?

Thermo Fisher Scientific offers complementary serum-free reagents including Gibco TrypLE Select Enzyme (1X and 10X), GlutaMAX Supplement, and AlbuMAX I and II Lipid-Rich BSA. For specialized cell lines and manufacturing goals, teams can also define component and concentration specifications through Gibco Media by Design Services.

spot_img

Subscribe Now

    Hot Topics

    spot_img